prof. dr. Xavier Verhelst
- Work address
-
C. Heymanslaan 10, ingang 12 - verdieping 6
9000 Gent - XAVIER.VERHELST@UGent.be
- ORCID iD
-
0000-0002-2798-5415
Show
Sort by
-
Impact on follow-up strategies in patients with primary sclerosing cholangitis
-
Glycomics-based serum marker as reliable tool for assessment of viral response after treatment with direct-acting antiviral drugs in hepatitis C virus infection
-
Long-term obeticholic acid (OCA) for primary biliary cholangitis (PBC) in a clinical trial improved event free survival (death, liver transplant and hepatic decompensation) compared to external controls from the GLOBAL PBC real-world database
-
Yttrium-90 radioembolization versus drug-eluting beads chemoembolization for unresectable hepatocellular carcinoma: results from the TRACE phase 2 randomized controlled trial
-
Pretransplant alterations in serum protein glycosylation are associated to risk of hcc recurrence after liver transplantation and provide a potential prognostic biomarker: a proof-of-concept study
-
Validation of a glycomics-based test associated with risk of HCC development in cirrhosis
-
A multicentric study to estimate mortality and graft loss risk after liver transplantation (LT) in patients with recurrent primary biliary cholangitis (PBC)
-
Enhanced liver fibrosis score correlates with transient elastography in patients with treated autoimmune hepatitis
-
Neurometabolic and gliovascular changes in murine hepatic encephalopathy
-
ADIPOSE TISSUE INSULIN RESISTANCE IS A DETERMINANT OF DISEASE SEVERITY IN PEDIATRIC NONALCOHOLIC FATTY LIVER DISEASE